Incidence and Prevalence of Coronavirus Disease 2019 Within a Healthcare Worker Cohort During the First Year of the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic
Overview
Authors
Affiliations
Background: Preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2_ infections in healthcare workers (HCWs) is critical for healthcare delivery. We aimed to estimate and characterize the prevalence and incidence of coronavirus disease 2019 (COVID-19) in a US HCW cohort and to identify risk factors associated with infection.
Methods: We conducted a longitudinal cohort study of HCWs at 3 Bay Area medical centers using serial surveys and SARS-CoV-2 viral and orthogonal serological testing, including measurement of neutralizing antibodies. We estimated baseline prevalence and cumulative incidence of COVID-19. We performed multivariable Cox proportional hazards models to estimate associations of baseline factors with incident infections and evaluated the impact of time-varying exposures on time to COVID-19 using marginal structural models.
Results: A total of 2435 HCWs contributed 768 person-years of follow-up time. We identified 21 of 2435 individuals with prevalent infection, resulting in a baseline prevalence of 0.86% (95% confidence interval [CI], .53%-1.32%). We identified 70 of 2414 incident infections (2.9%), yielding a cumulative incidence rate of 9.11 cases per 100 person-years (95% CI, 7.11-11.52). Community contact with a known COVID-19 case was most strongly correlated with increased hazard for infection (hazard ratio, 8.1 [95% CI, 3.8-17.5]). High-risk work-related exposures (ie, breach in protective measures) drove an association between work exposure and infection (hazard ratio, 2.5 [95% CI, 1.3-4.8). More cases were identified in HCWs when community case rates were high.
Conclusions: We observed modest COVID-19 incidence despite consistent exposure at work. Community contact was strongly associated with infections, but contact at work was not unless accompanied by high-risk exposure.
Bansal A, Trieu M, Eriksson E, Zhou F, McVernon J, Brokstad K Sci Rep. 2025; 15(1):4705.
PMID: 39922967 PMC: 11807171. DOI: 10.1038/s41598-025-89472-5.
Janke C, Rubio-Acero R, Weigert M, Reinkemeyer C, Khazaei Y, Kleinlein L Viruses. 2024; 16(10).
PMID: 39459890 PMC: 11512372. DOI: 10.3390/v16101556.
Investigating the Role of Serotonin Levels in Cognitive Impairments Associated with Long COVID-19.
Eslami Z, Joshaghani H Chonnam Med J. 2024; 60(3):141-146.
PMID: 39381125 PMC: 11458317. DOI: 10.4068/cmj.2024.60.3.141.
Kasztelewicz B, Skrok K, Burzynska J, Migdal M, Dzierzanowska-Fangrat K PLoS One. 2024; 19(5):e0301612.
PMID: 38781220 PMC: 11115228. DOI: 10.1371/journal.pone.0301612.
Mansoor A, ONeil C, McDonald D, Fraser V, Babcock H, Kwon J Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e81.
PMID: 38721487 PMC: 11077591. DOI: 10.1017/ash.2024.72.